|
|
|
| A stable and reliable animal model for hepatocellular carcinoma with portal vein tumor thrombus |
| Zong-Tao Chai a , Zhen-Hua Chen a , Xiu-Ping Zhang a , b , Jin-Kai Feng a , Zong-Han Liu a , Shu-Qun Cheng a , ∗ |
a Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, 225 Changhai Road, Shanghai 200433,
China
b Faculty of Hepato-Biliary-Pancreatic Surgery, the First Medical Center of Chinese People’s Liberation Army (PLA) General Hospital, Beijing 100039, China
∗ Corresponding author.
E-mail address: chengshuqun@aliyun.com (S.-Q. Cheng). |
|
|
|
|
Abstract Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide [1,2]. Portal vein tumor thrombus (PVTT) has been demonstrated to be a poor prognostic indicator for HCC [3–5]. However, effective treatment for the condition is still limited. Understanding the insight into the molecular mechanisms behind PVTT development may help to establish a new therapeutic strategy. Animal models which mimic the development of PVTT in humans are necessary to figure out the molecular mechanisms behind PVTT development. Currently, a wide range of animal models have been established for HCC from different angles, including chemically-induced models like diethylnitrosamine, carbon tetrachloride, thioacetamide, and phenobarbital, geneticallyengineered mouse (GEM) models like Wnt/ β-catenin signaling pathway (CTNNB1), telomerase reverse transcriptase (TERT) activation, aflatoxin B1 and HBV infection, and engrafted models [6–8]. However, all the above animal models cannot be used in the study of PVTT, since these models were not able to present all the histological, physiological, and clinical features of human PVTT.
|
|
|
|
|
|
|
|
|
2022, Vol. 21 
